Skip to content

Effective plasma concentrations of remifentanil, esketamine, or oliceridine for suppressing stress during transperineal prostate biopsy when propofol is continuously infused.

Effective plasma concentrations of remifentanil, esketamine, or oliceridine for suppressing stress during transperineal prostate biopsy when propofol is continuously infused.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112064
Enrollment
Unknown
Registered
2025-11-10
Start date
2025-11-25
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless prostate biopsy

Interventions

Propofol and Remifentanil group(R group):Remifentanil
Propofol and Esketamine group(E group):Esketamine
Propofol and Ozelidine Group(O group):Ozelidine

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for transperineal prostate biopsy; 2. Age 18–85 years; 3. Body Mass Index (BMI) 18–30 kg/m^2 ; 4. American Society of Anesthesiologists (ASA) classification I–III; 5. Preoperative assessment indicates no difficult airway.

Exclusion criteria

Exclusion criteria: 1. Patient refuses to participate in the study; 2. History of severe heart, brain, lung, liver, kidney, or metabolic diseases; 3. Patients with gastrointestinal obstruction or high risk of reflux aspiration; 4. History of abnormal surgical anesthesia recovery; 5. Patients with sinus bradycardia or atrioventricular block; 6. History of acute respiratory inflammation within 2 weeks that has not been cured; 7. Preoperative hypertension patients >180/90 mmHg or hypotension patients <90/60 mmHg; 8. Patients with neuromuscular disorders or mental illnesses; 9. Hemoglobin level below 90 g/L; 10. Suspected abuse of narcotic analgesics or sedatives; 11. Predicted or previously experienced difficult airway; 12. Known allergy to oliceridine, opioids, or esketamine; 13. Concurrent use of other sedative or analgesic drugs within 15 minutes before, during, or after surgery (including injections, oral drugs, and related traditional Chinese medicine); 14. Uncooperative or unable to communicate patients.

Design outcomes

Primary

MeasureTime frame
EC95 of Remifentanil in the R group;Degree of respiratory depression;EC95 of Esketamine in the E group;EC95 of Oxeladin in the O group;

Secondary

MeasureTime frame
Each group's EC50;Patient and operator satisfaction;Administer an additional dose of propofol;Lowest blood oxygen saturation;Loop parameter;

Countries

China

Contacts

Public ContactYi Zhou

Shanghai Changhai Hospital

Yizhoumz@163.com+86 137 6129 3168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026